Diadema Partners LP Lava Therapeutics Nv Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Diadema Partners LP holds 21,508 shares of LVTX stock, worth $20,002. This represents 0.01% of its overall portfolio holdings.
Number of Shares
21,508Holding current value
$20,002% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding LVTX
# of Institutions
23Shares Held
3.36MCall Options Held
100Put Options Held
200-
Redmile Group, LLC San Francisco, CA2.07MShares$1.93 Million0.16% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$717,8420.33% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3126KShares$117,4850.03% of portfolio
-
Pathway Financial Advisors LLC103KShares$95,3250.02% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA65KShares$60,4500.0% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $24M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...